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Abstract
Background: PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared
to conventional imaging and results in a change of treatment in a remarkable high number of patients. Radiotherapy
with dose escalation to the former prostate bed has been associated with improved biochemical recurrence-free
survival. Thus, it can be hypothesised that PSMA PET/CT-based radiotherapy might improve the prognosis
of these patients.
Methods: One hundred twenty-nine patients underwent PSMA PET/CT due to biochemical persistence (52%) or
recurrence (48%) after radical prostatectomy without evidence of distant metastases (February 2014–May 2017) and
received PSMA PET/CT-based radiotherapy. Biochemical recurrence free survival (PSA≤ 0.2 ng/ml) was defined as the
study endpoint.
Results: Patients with biochemical persistence were significantly more often high-risk patients with significantly
shorter time interval before PSMA PET/CT than patients with biochemical recurrence. Patients with biochemical
recurrence had significantly more often no evidence of disease or local recurrence only in PSMA PET/CT, whereas
patients with biochemical persistence had significantly more often lymph node involvement. Seventy-three
patients were started on antiandrogen therapy prior to radiotherapy due to macroscopic disease in PSMA
PET/CT. Cumulatively, 70 (66–70.6) Gy was delivered to local macroscopic tumor, 66 (63–66) Gy to the prostate
fossa, 61.6 (53.2–66) Gy to PET-positive lymph nodes and 50.4 (45–52.3) Gy to lymphatic pathways. Median PSA after
radiotherapy was 0.07 ng/ml with 74% of patients having a PSA ≤ 0.1 ng/ml. After a median follow-up of 20 months,
median PSA was 0.07 ng/ml with ongoing antiandrogen therapy in 30 patients. PET-positive patients without
antiandrogen therapy at last follow-up (45 patients) had a median PSA of 0.05 ng/ml with 89% of all patients,
94% of patients with biochemical recurrence and 82% of patients with biochemical persistence having a PSA≤ 0.2 ng/ml.
Post-radiotherapy PSA ≤ 0.1 ng/ml and biochemical recurrence vs. persistence were significantly associated
with a PSA ≤ 0.2 ng/ml at last follow-up.
Conclusions: PSMA PET/CT-based radiotherapy is an effective local salvage treatment option with significant PSA
response in patients with biochemical recurrence or persistence after radical prostatectomy leading to deferral of
long-term ADT or systemic therapy.
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Background
68Ga-PSMA-HBED-CC (68Ga-PSMA) positron emission
tomography/computed tomography (PET/CT) has emerged
as the gold standard in staging prostate cancer patients
with biochemical persistence or recurrence after radical
prostatectomy compared to conventional imaging like
computed tomography (CT) or magnetic resonance
imaging (MRI) [1, 2] and choline PET/CT [3]. PSMA
PET/CT results in a modification of treatment e.g.
addition of antiandrogen therapy (ADT), enlargement
of the irradiated volume or even omission of radiotherapy
in the event of advanced, metastatic disease in a remarkable
high number of patients (33.8–76%) with biochemical
persistence or recurrence [4–10]. Unlike conventional
imaging, PET with 68Ga-PSMA offers the unique pos-
sibility of visualising prostate cancer residual disease
or recurrence at very low prostate-specific antigen
(PSA) levels with 58.3% of PET-positive results found
in a PSA range of 0.51–1.0 ng/ml [11–16]. Data stemming
from retrospective dose escalation studies in patients with
biochemical recurrence after radical prostatectomy
confirmed that a higher radiation dose is significantly
associated with a risk reduction in biochemical failure
[17] and was not associated with a difference in acute
grade 2 and 3 genitourinary or gastrointestinal toxicity
in a single randomised study - SAKK 09/10 when
irradiating the former prostate bed with 64 Gy vs.
70 Gy [18]. Since the advent of PSMA PET/CT, dose
escalation to macroscopic tumor residual disease or
recurrence is now more precisely possible and is
potentially associated with a further improvement of
biochemical recurrence-free survival. Currently, there
is paucity of data regarding outcome after PSMA PET/
CT-based surgical [19–21] or radiotherapeutic treatment
[22–27] in patients with persistent or recurrent prostate
cancer. Since February 2014, offering PSMA PET/CT
to all patients with recurrent or persistent prostate
cancer after radical prostatectomy at our department,
we evaluated the outcome following PSMA PET/CT-
based radiotherapy.
Methods
Study population
In February 2014, 68Ga-PSMA PET/CT prior to radiother-
apy was introduced at our department as the standard
diagnostic staging tool routinely utilised in prostate cancer
patients. A total of 176 consecutive patients underwent
PSMA PET/CT prior to radiotherapy. 129/176 (73%)
patients received PSMA PET/CT due to biochemical
persistence (52%) or recurrence (48%) after radical prosta-
tectomy without evidence of distant metastases (Table 1).
47/176 (27%) patients were excluded from the analysis: In
20/47 patients PSMA PET/CT was performed in the
primary setting and in 27/47 patients distant metastatic
disease was diagnosed. All patients provided written
informed consent to undergo 68Ga-PSMA PET/CT. This
retrospective analysis was performed in compliance
with the principles of the Declaration of Helsinki and
its subsequent amendments [28] and was approved by
the Ethics Committee of our Medical Faculty.
Treatment application and follow up
All patients received PSMA PET/CT as staging prior to
radiotherapy. Treatment management following PSMA
PET, e.g. initiation of ADT for PET-positive results,
treatment of pelvic lymphatic pathways and simultaneous
Table 1 Patients’ characteristics
All patients PSA relapse PSA persistence
N 129 62 67
Median age 72 (47–83) 74 (50–83) 70 (47–83)
Tumor stage
pT2 43 (33%) 35 (57%) 8 (12%)
pT3a 36 (28%) 17 (27%) 19 (28%)
pT3b 48 (37%) 8 (13%) 40 (60%)
pT4 2 (2%) 2 (3%) –
Nodal stage
pN0 79 (61%) 46 (74%) 33 (49%)
pN1 37 (29%) 8 (13%) 29 (43%)
pNx/cN0 13 (10%) 8 (13%) 5 (8%)
Positive surgical margins 60 (47%) 16 (26%) 44 (66%)
Gleason score
6–7 70 (54%) 44 (71%) 26 (39%)
8–9 59 (46%) 18 (29%) 41 (61%)
Median PSA at RPE 10.85
(2.37–190)
8.55
(2.37–48)
18.05
(3.99–190)
Postoperative PSA 0.12
(< 0.03–40.13)
< 0.03 0.47
(0.08–40.13)
Months since RPE 33 (2–192) 61 (9–192) 8 (2–94)
Median PSA at PSMA
PET/CT
0.62
(0.13–40.13)
0.44
(0.15–6.24)
0.90
(0.13–40.13)
Median PSA at PSMA
PET/CT in PET positive pts
1.09
(0.14–40.13)
0.78
(0.27–6.24)
1.6
(0.14–40.13)
Median PSA at PSMA
PET/CT in PET negative pts
0.3
(0.13–3.24)
0.3
(0.13–3.24)
0.34
(0.13–1.33)
PSMA PET/CT result
Negative 51 (39%) 31 (50%) 20 (30%)
Fossa recurrence only 24 (19%) 16 (26%) 8 (12%)
Lymph node positive
only
42 (33%) 12 (19%) 30 (45%)
Fossa and lymph node
recurrence
12 (9%) 3 (5%) 9 (13%)
Pts patients, PSA prostate specific antigen, RPE radical prostatectomy,
PSMA PET/CT prostate-specific membrane antigen positron emission
tomography/computed tomography
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boost volumes to local recurrence or lymph node recur-
rence supplementary to the irradiation of former prostate
was documented for each patient. Follow-up examination
was first performed 3 months after irradiation and then
every six to 12 months. Follow-up time was defined as the
interval in months between radiotherapy and the last
recorded PSA.
PSMA ligand and PET/CT imaging
PSMA-HBED-CC was radiolabelled with 68Ga3+ from a
68Ge/68Ga generator system (GalliaPharm®, Eckert &
Ziegler AG, Berlin, Germany) using an automated
synthesis module (GRP, Scintomics GmbH, Munich,
Germany) and pre-packed cassettes (ABX GmbH,
Radeberg, Germany) as described previously for a different
PSMA ligand by Weineisen et al. [29]. 68Ga-PSMA PET/
CT images extending from the base of the skull to the
mid-thigh were acquired. PET/CT scan was obtained with
intravenous injection of iodine-containing contrast agent
(Ultravist 300, Bayer Pharma AG, Berlin, Germany; or
Imeron 300, Bracco, Konstanz; 2.5 mL/s; in portal venous
phase) 60 min after almost simultaneous intravenous
administration of 20 mg furosemide and 68Ga-PSMA
(mean 205 megabecquerel (MBq)). Directly prior to the
PET/CT scan, patients were implored to empty their
bladders to minimise tracer accumulation.
Image interpretation
PET/CT was interpreted by a consensus read by one nu-
clear medicine physician and one radiologist. Location of
lesions was each determined by CT. PET-positive lesions
were visually identified by 68Ga-PSMA uptake above
background and not associated with the physiologic up-
take. CT-positive nodes were defined by increased short
axis diameter, loss of fatty hilum, or increased contrast
enhancement. Local recurrence was identified by 68Ga-
PSMA uptake and/or increased contrast enhancement in
the prostate bed [30].
Radiotherapy treatment
Planning CT was done in supine position. Patients were
advised to have a full bladder and an empty rectum. All
patients received radiotherapy with intensity modulated
RT (IMRT) or volumetric arc therapy (VMAT) and
image-guided RT (IGRT) techniques (2–5 times/week)
using cone-beam CTs. Target delineation was performed
according to the Radiation Therapy Oncology Group
(RTOG) atlas for salvage prostate cancer. The clinical
target volume (CTV) of the former prostate gland is
defined superiorly as 5 mm above the inferior border of
the vas deferens remnant, inferiorly as above the top of
penile bulb, anteriorly by the pubic symphysis, poster-
iorly by the anterior rectum and laterally by the medial
edge of the obturator internus muscle. Planning target
volume (PTV) was derived by expanding the CTV by a
5–7 mm margin in all directions. Generally, an overall
dose of 66 Gy with 2 Gy per fraction was applied to the
prostate bed and 50.4 Gy with 1.8 Gy per fraction to the
lymphatic pathways when PET-positive nodal involve-
ment was detected. PET-positive pelvic lymph nodes
were treated with a simultaneous-integrated boost
(1.85–2.2 Gy per fraction). Likewise, a simultaneous
integrated/sequential boost (2.0–2.14 Gy per fraction)
was applied in case of local recurrence in PSMA PET/
CT. The delineation of the gross tumor volume (GTV),
i.e. local recurrence or suspicious lymph, nodes was
based on 68Ga-PSMA uptake above background and
increased contrast enhancement in the prostate bed and
on increased short axis diameter, loss of fatty hilum,
or increased contrast enhancement of the respective
lymph nodes.
Statistical analysis
For statistical analysis, SPSS Statistics 24 (IBM, New
York, USA) was used. Time to event data was calculated
using the Kaplan-Meier method. Differences between
subgroups were compared using log rank test with a
p value of < 0.05 considered statistically significant. Uni-
and multivariate logistic regression analysis was used to
identify predictors for treatment response.
Results
Patients’ characteristics and PSMA PET results
One hundred twenty-nine consecutive patients were in-
cluded in this retrospective analysis on outcome after
PSMA PET/CT-based radiotherapy for biochemical per-
sistence (48%) or recurrence (52%) following radical
prostatectomy. Evidence of metastatic disease was con-
sidered an exclusion criterion. Patients with biochemical
persistence were significantly more often high-risk pa-
tients with higher overall pathologic tumor stage (60%
pT3b; p < 0.05), pathologic pelvic lymph node involve-
ment (43% vs. 13% pN1; p < 0.05), positive surgical
margins (66% vs. 26%; p < 0.05) and higher Gleason Score
8–9 (61% vs. 29%%; p < 0.05). Biochemical relapse was
predominantly associated with low- to intermediate-risk
[pT2 (57%), pN0 (74%) and Gleason Score 6–7 (71%)].
All patients with biochemical recurrence had a non-
detectable PSA postoperatively and a longer time inter-
val until PSMA PET/CT vs. patients with biochemical
persistence (61 vs. 8 months; p < 0.05). Overall, most
patients (78/129; 60%) had PET-positive findings.
Patients with biochemical recurrence were significantly
more often PSMA PET negative (50% vs. 30%) or if
PSMA PET positive, they showed more often evidence
of local recurrence (26% vs. 12%; p < 0.05). On the
other hand, patients with biochemical persistence had
significantly more often PET-positive lymph nodes with
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(13% vs. 5%) or without evidence of macroscopic
tumour in the prostate bed (45% vs. 19%). A negative
PSMA PET scan was significantly associated with lower
PSA levels: 76% of these patients had a PSA level ≤ 0.5 ng/
ml compared to patients with a positive scan with 74% of
these patients having PSA levels > 0.5 ng/ml. Baseline
patients’ characteristics are shown in Table 1.
Management of PET-positive lesions and
patients’ outcome
Androgen deprivation therapy (ADT) prior to radiother-
apy was initiated in PET-positive findings (73/129). Five
patients refused ADT. Fifty-nine percent (43/73) of these
patients discontinued ADT after a median duration of 5
(2–25) months. All patients received VMAT- or IMRT-
based radiotherapy to a median total dose of 66 (63–66)
Gy to the prostate bed and 50.4 (45–52.3) Gy to the
lymphatic pathways when PET-positive nodal involve-
ment was detected with simultaneous integrated boost
(SIB) to PET-positive lymph nodes (median dose 61.6 Gy;
53.2–66 Gy) (Fig. 1). In the case of local tumour recur-
rence/persistence, a SIB was delivered to a median total
dose of 70 (66–70.6) Gy.
Median follow-up was 20 months (3–42). Median
post-radiotherapy PSA was 0.07 ng/ml (< 0.03–13.71)
with 74% of patients presenting with a PSA ≤ 0.1 ng/ml
and 81% with a PSA ≤ 0.2 ng/ml. At last median follow-
up, median PSA was 0.07 ng/ml (< 0.03–35) with 82% of
all patients having a PSA ≤ 0.1 ng/ml and 84% a
PSA ≤ 0.2 ng/ml (Fig. 2a). There were 30 (41%) patients
with ongoing ADT after a median follow-up of 20 months
with 79%/83% having a PSA ≤ 0.1/0.2 ng/ml, respectively.
Patients without ongoing ADT (91 patients) had a median
PSA of 0.07 ng/ml (< 0.03–35) with 83%/85% presenting
with a PSA ≤ 0.1/0.2 ng/ml, respectively (Fig. 2b). PET-
positive patients with discontinued or refused ADT at last
follow-up (45 patients; 58%) had a median PSA of
0.05 ng/ml (< 0.03–35) with 89% of the entire cohort, 94%
of the subgroup with biochemical recurrence and 82%
with biochemical persistence having a PSA ≤ 0.2 ng/ml
(p = 0.019; Fig. 2d). ADT at last follow-up was more often
applied in the subgroup of patients with biochemical per-
sistence than biochemical recurrence (93% vs. 7%;
p < 0.05). Distant metastases at last follow-up were
only detected in the subgroup with biochemical persist-
ence (14/67; 21%). At the time of last analysis, all patients
were alive. Treatment characteristics and PSA response
are shown in Table 2 and Fig. 2.
Factors predicting PSA response at last follow-up
An uni- and multivariate analysis was conducted to
assess whether there was an association between tumour
specific variables and PSMA PET/CT imaging results
and a PSA ≤ 0.2 ng/ml at last follow-up. This was first
studied in all 129 patients including all 30 patients on
ADT at last follow-up (Table 3) and was repeated due
to possible confounding bias in patients without ADT
(99 patients; data not shown). Regardless of ADT
usage at last follow-up, there was no association between
a PSA ≤ 0.2 ng/ml at last follow-up and the following fac-
tors [ADT at time of irradiation, pre-RT PSA ≤/> 0.5 ng/
ml, Gleason Score (6–7 vs. 8–9), pT- and pN-stage, surgi-
cal margins (positive vs. negative), PSMA PET result
(negative or fossa recurrence only vs. PET-positive lymph
nodes), PSMA PET result (positive vs. negative), overall
dose ≤66.6Gy vs. >66Gy to the prostate fossa and overall
dose ≤50.4Gy vs. > 50.4Gy to pelvic lymph nodes]. A
post-radiotherapy PSA ≤ 0.1 ng/ml and biochemical
recurrence vs. persistence were significantly associated
with a PSA ≤ 0.2 ng/ml at last follow-up irrespective
of ongoing ADT. On multivariate analysis, a significant
association between post-radiotherapy PSA ≤ 0.1 ng/ml
and PSA ≤ 0.2 ng/ml at last follow-up was observed
irrespective of the study population.
Discussion
PSMA PET/CT is currently the best available imaging
technique to differentiate local relapse in the prostate
bed, pelvic lymph node metastases or even metastatic
disease in patients with biochemical persistence or
recurrence [31]. Particularly, in patients considered for
salvage radiation treatment, PSMA PET/CT has a high
Fig. 1 68Ga-PSMA PET/CT (a) and target volume with simultaneously integrated boost volume (b) to PET-positive lymph node
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detection rate of prostate cancer lesions outside the
prostatic fossa [15], corresponding to the number of
men failing after salvage irradiation of the prostate fossa.
Thus in 5%/19% of our patients treated due to biochem-
ical failure, PSMA PET/CT revealed pelvic nodal in-
volvement with/without local recurrence, respectively.
As expected, patients with biochemical persistence being
significantly more high-risk patients had a significantly
higher rate of PET-positive pelvic lymph node metasta-
ses with/without local disease (13%/45%). This leads to a
remarkable change in treatment e.g. the modification of
radiation fields, dose escalation to macroscopic tumour
lesions and initiation of ADT, as already extensively
studied in current literature [4–9].
Furthermore, PSMA PET/CT is especially sensitive in
identifying tumour recurrence at PSA levels well below
1.0 ng/ml [12], enabling radiotherapy initiation at PSA
levels that are still considered curable [32]. Currently, no
general recommendation for a PSA cut-off prior to post-
operative staging with PSMA PET/CT exists, although
some data suggest a PSA of 0.83 ng/ml as an optimal
cut-off value [33]. In comparison, PET-positive findings
were seen in our cohort at a slightly lower median PSA
(0.78 ng/ml) in patients with biochemical recurrence vs.
biochemical persistence (median PSA 1.6 ng/ml).
All patients with biochemical recurrence or persist-
ence underwent PSMA PET/CT-based radiation treat-
ment: absence of PET-positive disease resulted in
irradiation of the prostate bed exclusively, whereas in
the case of local recurrence a SIB was delivered.
Additionally, presence of PET-positive pelvic lymph
nodes resulted in irradiation of the pelvic basin with SIB
to the involved nodes.
Extrapolated from data for pN+ patients treated with
adjuvant radiotherapy and concurrent ADT [34, 35],
ADT was recommended for 2 years with evidence of
PET-positive lesions. Although, 73 patients were started
on ADT, about two-thirds discontinued prematurely
after a median time of 5 (2–25) months due to patients’
preferences.
Based on a median follow-up of 20 months and an
overall number of 129 patients, our analysis shows the
Fig. 2 a Biochemical recurrence free survival (≤0.2 ng/ml) in all patients (PSA persistence vs. PSA recurrence) at last follow-up. b Biochemical recurrence
free survival (≤0.2 ng/ml) in all patients without antiandrogen therapy (PSA persistence vs. PSA recurrence) at last follow-up. c Biochemical recurrence free
survival (≤0.2 ng/ml) in all PET-positive patients (PSA persistence vs. PSA recurrence) at last follow-up. d Biochemical recurrence free survival (≤0.2 ng/ml)
in all PET-positive patients without antiandrogen therapy (PSA persistence vs. PSA recurrence) at last follow-up
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high impact of PSMA PET/CT on oncologic outcome
and is in accordance with the currently limited number
of analyses on outcome after PSMA PET/CT-based
radiotherapy in persistent or recurrent prostate cancer
with mostly shorter follow-up [22–26]: Our analysis
shows that there is a high rate and long-lasting treat-
ment response to irradiation based on pre-treatment
Table 2 Treatment and response
All
patients
PSA
relapse
PSA
persistence
ADT
ADT with stop before
last follow up / duration
(months)
43 / 5
(2–25)
22 / 4.5
(2–23)
21 / 5.5
(2–25)
Ongoing ADT at last
follow up
30 3 27
No ADT 56 37 19
Median PSA before RT 0.62
(< 0.03–40.13)
0.44
(0.15–10.6)
0.90
(< 0.03–40.13)
RT
Former Prostate 66 Gy (63–66)
Lymphatic pathways 50.4 Gy (45–52.3)
Local recurrence 70 Gy (66–70.6)
PET pos. LN 61.6 Gy (53.2–66)
RT technique
VMAT/IMRT & IGRT All pts.
Median Follow-up (months) 20 (3–42)
First PSA after RT n = 121a n = 58b n = 63b
Median PSA 0.07
(< 0.03–13.71)
0.07
(< 0.03–0.56)
0.07
(< 0.03–13.71)
PSA≤ 0.1 ng/ml 89 (74%) 47 (81%) 42 (67%)
PSA≤ 0.2 ng/ml 98 (81%) 50 (86%) 48 (76%)
PSA at last median
follow-up
n = 121a n = 58b n = 63b
Median PSA 0.07
(< 0.03–35)
0.07
(< 0.03–1)
0.07
(0.01–35)
PSA≤ 0.1 ng/ml 82% 87% 77%
PSA≤ 0.2 ng/ml 84% 91% 78%
PSA at last median
follow-up with ADT
n = 30 n = 2 n = 28
Median PSA 0.06
(< 0.03–13.71)
< 0.03 0.07
(< 0.03–13.71)
PSA≤ 0.1 ng/ml 79% 100% 79%
PSA≤ 0.2 ng/ml 83% 100% 82%
PSA at last median
follow-up without ADT
n = 91 n = 56 n = 35
Median PSA 0.07
(< 0.03–35)
0.07
(< 0.03–1)
0.08
(< 0.03–35)
PSA≤ 0.1 ng/ml 83% 87% 78%
PSA≤ 0.2 ng/ml 85% 91% 78%
PSA at last median
follow-up in PET pos. pts
n = 72 n = 29 n = 43b
Median PSA 0.06
(< 0.03–35)
0.03
(< 0.03–0.46)
0.07
(< 0.03–35)
PSA≤ 0.1 ng/ml 84% 94% 77%
PSA≤ 0.2 ng/ml 86% 94% 79%
PSA at last median
follow-up in PET pos. pts
without ADT
n = 45 n = 27 n = 18
Table 2 Treatment and response (Continued)
All
patients
PSA
relapse
PSA
persistence
Median PSA 0.05
(< 0.03–35)
0.04
(< 0.03–0.46)
0.13
(< 0.03–35)
PSA≤ 0.1 ng/ml 89% 94% 82%
PSA≤ 0.2 ng/ml 89% 94% 82%
PSA at last follow-up
in PET neg. pts
n = 49 n = 29 n = 20
Median PSA 0.07
(< 0.03–3.23)
0.07
(< 0.03–1)
0.08
(< 0.03–3.23)
PSA≤ 0.1 ng/ml 78% 79% 77%
PSA≤ 0.2 ng/ml 83% 87% 77%
Clinical Progress
Distant Metastases 14
PSA prostate specific antigen, ADT androgen deprivation therapy, LN lymph nodes,
RT radiation therapy, VMAT volumetric modulated arc therapy, IMRT intensity
modulated radiotherapy, IGRT image guided radiotherapy
aPSA follow-up missing in eight patients
bPSA follow-up missing in four patients
Table 3 Association between treatment response (PSA ≤0.2 ng/ml)
at last follow-up and possibly interacting variables (logistic regression
analysis, all patients)
Association between treatment response and p-Valuea p-Valueb
ADT at time of RT 0.104 0.131
PRE-RT PSA ≤/> 0.5 ng/ml 0.226 0.188
Gleason Score (6–7 vs. 8–9) 0.129 0.791
pT stage 0.104 0.195
pN stage 0.341 0.908
Surgical margins 0.833 0.609
PSA after RT ≤ 0.1 ng/ml 0.008 0.007
PSMA PET result
(Negative or fossa recurrence only vs.
lymph node recurrence)
0.623 0.999
PSMA PET result
(positive vs. negative)
0.263 0.693
Dose escalation prostate fossa
≤66.6Gy vs. >66Gy
0.324 0.122
Dose escalation pelvic lymph nodes
≤50.4Gy vs. >50.4Gy
0.371 0.999
RT indication (biochemical recurrence vs.
biochemical persistence)
0.026 0.211
PSA prostate specific antigen, ADT androgen deprivation therapy, PRE-RT
PSA PSA pre-radiotherapy, RT radiotherapy
aunivariate and bmultivariate binary logistic regression analysis
*p < 0.05 statistically significant
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PSMA PET/CT in patients with biochemical recurrence
or persistence with 84% presenting with a PSA ≤ 0.2 ng/
ml at a median follow-up of 20 months. When restrict-
ing the analysis to PET-positive patients without ADT at
last follow-up (45 patients), the most challenging and
interesting subgroup, 89% had a PSA ≤ 0.2 ng/ml.
Splitting this subgroup further into patients with
biochemical recurrence vs. persistence, the number of
patients with PSA ≤ 0.2 ng/ml after a median follow-up
of 20 months becomes even more divergent: 94% of
patients with biochemical recurrence and evidence of
PET-positive disease without ADT at last median
follow up had a PSA level ≤ 0.1 ng/ml and ≤0.2 ng/ml
vs. 82% of patients with biochemical persistence hav-
ing a PSA ≤ 0.2 ng/ml (p = 0.019; Fig. 2d). This mainly
reflects the fact that men with biochemical recurrence
in our cohort had significantly more local relapses
within the prostate fossa compared to men with
biochemical persistence with significantly more pelvic
nodal involvement in PSMA PET/CT. Emmett et al.
[23] likewise reported on treatment outcome from
PSMA PET/CT informed salvage radiation treatment in
men with rising PSA following radical prostatectomy:
based on a shorter median follow-up of 10.5 months, they
also saw a high number of treatment response to radio-
therapy (29/36 patients; 83%) when disease was confined
to prostate fossa compared to patients with PET-positive
nodal involvement (16/26 patients; 61%). Furthermore,
the high number of 94% of PET-positive patients with
biochemical recurrence having a PSA ≤ 0.1 ng/ml after
20 months in our cohort compares nicely to the analysis
of Zschaeck et al. [22] on 20 recurrent high-risk pros-
tate cancer patients with a median PSA of 0.15 ng/ml
after a median follow-up of 29 months.
Achieving a post-radiotherapy PSA nadir ≤0.1 ng/ml and
radiotherapy indication (biochemical recurrence vs. persist-
ence) were the only factors associated with a PSA ≤ 0.2 ng/
ml at last follow-up in our cohort. This is in accordance
with the recent data by Bartkowiak et al. [36] demonstrat-
ing that men with undetectable post-radiotherapy PSA have
lower rates of metastases and a better overall survival.
Unlike the findings by Emmett et al. [23] that PSMA PET
result (negative or fossa recurrence only vs. PET-positive
lymph nodes vs. distant metastases) is predictive of treat-
ment response to salvage radiotherapy, we did not see
any correlation between PSMA PET result (negative
or fossa recurrence only vs. PET-positive lymph nodes) and
biochemical recurrence-free survival. This is most likely to
due to the fact, that we restricted our analysis to non-
metastasised patients in contrast to the study by Emmett et
al. which included patients with metastatic disease.
Furthermore, contrary to data from literature showing
a strong association between pre-RT PSA and progression-
free survival [32, 36], there was no such association
between pre-RT PSA ≤/> 0.5 ng/ml and PSA ≤0.2 ng/ml at
last follow-up in our cohort.
Our study has several limitations mainly as it is a retro-
spective study. Moreover, there was a low number of
patients with biochemical recurrence that limits the
statistical power of a multivariate analysis. Thus, a
validation of our results within a larger cohort would
be preferable.
Currently, PSMA PET/CT is the best diagnostic tool
available for patients with rising PSA post-radical prosta-
tectomy. Yet, it may still underestimate the true extent
of disease in particular for the detection of small volume
lymph nodes below 4 mm due to the inherent physical
limitations of PET imaging [1, 37] as well as for lesions
close to the prostate fossa overshadowed by the SUV
and radioactivity concentration within the bladder
[38, 39]. The implementation of novel 18F–labeled
PSMA tracers may overcome this issue because of its
low clearance via the urinary tract. Consequently, one
third of our PET-negative patients, all treated with irra-
diation to the prostate fossa, failed biochemically at last
follow-up. Since all data available consistently document
that PSA control is significantly better when radiotherapy
is commenced as early as possible [32, 40, 41], it is never-
theless not justifiable to wait until PSA is in an optimal
range or surpasses a cut-off for diagnostic assessment.
Conclusions
Currently, PSMA PET/CT is the best available imaging
technique in patients with persistent or rising PSA after
radical prostatectomy and detects a high number of
lesions not confined to the prostate fossa. PSMA PET/
CT enables tailoring of radiation treatment with adapta-
tion of irradiated volumes. After a median follow-up of
20 months, nearly 90% of men with PET-positive lesions
without any ongoing antiandrogen therapy at last
follow-up did not show any evidence of biochemical
recurrence after PSMA PET/CT-based radiotherapy lead-
ing to a potential deferral of ADT or systemic therapy.
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